Impact of Biomarkers on Personalized Medicine.

The field of personalized medicine that involves the use of measuring biomarkers in clinical samples is an area of high interest and one that has tremendous impact on drug development. With the emergence of more sensitive and specific technologies that are now able to be run in clinical settings and the ability to accurately measure biomarkers, there is a need to understand how biomarkers are defined, how they are used in clinical trials, and most importantly how they are used in conjunction with drug treatment. Biomarker approaches have entered into early clinical trials and are increasingly being used to develop new diagnostics that help to differentiate or stratify the likely outcomes of therapeutic intervention. Tremendous efforts have been made to date to discover novel biomarkers for use in clinical practice. Still, the number of markers that make it into clinical practice is rather low. In the next following chapters, we will explain the various classifications of biomarkers, how they are applied, measured, and used in personalized medicine specifically focusing on how they are used in de-risking the 10 plus years drug development process and lastly how they are validated and transformed into companion diagnostic assays.

[1]  D. Gerhold,et al.  Kidney Injury Molecule-1 Outperforms Traditional Biomarkers of Kidney Injury in Multi-site Preclinical Biomarker Qualification Studies , 2010, Nature Biotechnology.

[2]  M. Ziman,et al.  Serologic Autoantibodies as Diagnostic Cancer Biomarkers—A Review , 2013, Cancer Epidemiology, Biomarkers & Prevention.

[3]  Armin Koch,et al.  Personalized medicine using DNA biomarkers: a review , 2012, Human Genetics.

[4]  G. Eknoyan,et al.  A history of diabetes mellitus or how a disease of the kidneys evolved into a kidney disease. , 2005, Advances in chronic kidney disease.

[5]  G. Calin,et al.  miRNAs and long noncoding RNAs as biomarkers in human diseases , 2013, Expert review of molecular diagnostics.

[6]  C. Levy,et al.  Influence of renal insufficiency on levels of serum ribonuclease in patients with multiple myeloma. , 1977, Journal of the National Cancer Institute.

[7]  René Bernards,et al.  Taming the dragon: genomic biomarkers to individualize the treatment of cancer , 2011, Nature Medicine.

[8]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumors , 2012, Nature.

[9]  Darren Plant,et al.  Genetic and epigenetic predictors of responsiveness to treatment in RA , 2014, Nature Reviews Rheumatology.

[10]  C. Pui,et al.  Pharmacogenomics and Individualized Medicine: Translating Science Into Practice , 2012, Clinical pharmacology and therapeutics.

[11]  K. Strimbu,et al.  What are biomarkers? , 2010, Current opinion in HIV and AIDS.

[12]  S. Hanash,et al.  Emerging molecular biomarkers—blood-based strategies to detect and monitor cancer , 2011, Nature Reviews Clinical Oncology.

[13]  Duncan Ayers,et al.  Long Non-Coding RNAs: Novel Emergent Biomarkers for Cancer Diagnostics , 2013 .

[14]  Olufunmilayo I. Olopade,et al.  Breast cancer risk associated with BRCA1 and BRCA2 in diverse populations , 2007, Nature Reviews Cancer.

[15]  O. Nemirovskiy,et al.  Design and validation of an immunoaffinity LC-MS/MS assay for the quantification of a collagen type II neoepitope peptide in human urine: application as a biomarker of osteoarthritis. , 2010, Methods in molecular biology.

[16]  D. DeMets,et al.  Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework , 2001, Clinical pharmacology and therapeutics.

[17]  D. Hoon,et al.  Epigenetic biomarkers in skin cancer. , 2014, Cancer letters.

[18]  Alison Stopeck,et al.  Circulating tumor cells, disease progression, and survival in metastatic breast cancer. , 2004, The New England journal of medicine.

[19]  Steven J. M. Jones,et al.  Comprehensive molecular characterization of human colon and rectal cancer , 2012, Nature.

[20]  D. Chan,et al.  Translation of proteomic biomarkers into FDA approved cancer diagnostics: issues and challenges , 2013, Clinical Proteomics.

[21]  C. Milne,et al.  Trial watch: Personalized medicines in late-stage development , 2014, Nature Reviews Drug Discovery.

[22]  K. Pantel,et al.  Real-time liquid biopsy in cancer patients: fact or fiction? , 2013, Cancer research.